通过工程化纳米药物开发个性化抗转移策略。
Development of individualized anti-metastasis strategies by engineering nanomedicines.
作者信息
He Qianjun, Guo Shengrong, Qian Zhiyong, Chen Xiaoyuan
机构信息
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, P. R. China.
Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892, USA.
出版信息
Chem Soc Rev. 2015 Oct 7;44(17):6258-6286. doi: 10.1039/c4cs00511b. Epub 2015 Jun 9.
Metastasis is deadly and also tough to treat as it is much more complicated than the primary tumour. Anti-metastasis approaches available so far are far from being optimal. A variety of nanomedicine formulae provide a plethora of opportunities for developing new strategies and means for tackling metastasis. It should be noted that individualized anti-metastatic nanomedicines are different from common anti-cancer nanomedicines as they specifically target different populations of malignant cells. This review briefly introduces the features of the metastatic cascade, and proposes a series of nanomedicine-based anti-metastasis strategies aiming to block each metastatic step. Moreover, we also concisely introduce the advantages of several promising nanoparticle platforms and their potential for constructing state-of-the-art individualized anti-metastatic nanomedicines.
转移是致命的，而且由于其比原发性肿瘤复杂得多，所以治疗起来也很困难。目前可用的抗转移方法远非最佳。多种纳米药物配方为开发应对转移的新策略和手段提供了大量机会。应当指出的是，个体化抗转移纳米药物不同于普通抗癌纳米药物，因为它们专门针对不同群体的恶性细胞。本文简要介绍了转移级联反应的特征，并提出了一系列基于纳米药物的抗转移策略，旨在阻断转移的每一步。此外，我们还简要介绍了几种有前景的纳米颗粒平台的优势及其构建先进个体化抗转移纳米药物的潜力。
Zotero 插件